Cenix BioScience Delivers on Target Discovery Collaboration
The method of identification, based on detailed analysis of RNAi-induced loss-of-function phenotypes in living human cells, conveys upon these targets a significantly stronger patho-physiological relevance than that typically seen for targets identified by less probative "first-wave" genomics methodologies of recent years. As such, the higher level of validation delivered by Cenix inherently offers superior predictive value regarding the future therapeutic potential of drug candidates developed from these targets.
According to the collaboration announced in December 2003, Bayer acquired the first option to secure all rights to new target-related intellectual property generated by the project. As a result, Bayer's decision to seek patent protection on the present targets triggered unspecified milestone payments to Cenix.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.